InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,437.70
(
-1.53%
)
US TECH 100
18,446.80
(
-2.10%
)
Dow Jones
40,221.50
(
-1.52%
)
Brent Oil
80.07
(
-1.77%
)
Bitcoin
62,560.38
(
-3.14%
)
Post# of 252759
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

miljenko

Send PM Follow Ignore
Followers 4
Posts 313
Boards Moderated 0
Alias Born 11/21/2011

miljenko

Re: DewDiligence post# 231094

Saturday, 04/18/2020 12:06:12 AM

Saturday, April 18, 2020 12:06:12 AM

Post# of 252759
<To my knowledge, VIR’s is the only HBV program planning to incorporate peg-IFN (in the phase-2 trial). Fans of JNJ/ARWR's program claim VIR's use of peg-IFN is a sign of weakness. Do you concur?>

JNJ is combining 3989 with capsid assembly inhibitor JNJ-56136379, and with Entecavir/Tenofovir...so is their siRNA *weak* on its own as well? Or, is it about cure, and not viral suppression only.
Adding PEG-IFN is logical, they may as well use Entecavir/Tenofovir combination. From that, it is not weakness, they have no other choice.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up